Examination of chlorpromazine and other amphipathic drugs on the activity of lipopolysaccharide antagonists, E5564 and E5531.
The synthetic antagonists of lipopolysaccharide (LPS), E5531 and E5564, are analogs of the lipid A portion of LPS that not only lack agonistic activity but also inhibit the biological effects of LPS both in vitro and in vivo. The effects of LPS and these synthetic antagonists have been localized to the recently described Toll-like receptor 4 (TLR4). A recent report indicated that the naturally occurring LPS antagonist Rhodobacter sphaeroides LPS loses its antagonist properties and gains pro-inflammatory qualities in the presence of chlorpromazine and other amphipathic drugs. To determine whether these reported actions occur with our chemically defined LPS antagonists, we examined the effects of chlorpromazine, fluphenazine, trifluoperazine, and lidocaine on the antagonism elicited by RsLPS and E5531 in U373 cells, which produce IL-6 in response to LPS. We also tested the effects of these amphipathic molecules on the LPS-neutralizing activity of RsLPS and E5564 on LPS-induced TNF-alpha release in human whole blood. The results indicate that neither chlorpromazine, fluphenazine, trifluoperazine nor lidocaine alter the activity of E5531 or E5564 in an in vitro cell system or human whole blood. Furthermore, chlorpromazine did not affect the antagonistic activity of RsLPS or E5564 on IL-6 generation by peripheral blood mononuclear cells. Thus, based on these data, our purified synthetic LPS-antagonists do not appear to lose their antagonistic properties and/or become agonists in the presence of amphipathic agents or drugs.
Yang
H
H
Department of Molecular Biology/Biochemistry and Pharmacology, Signal Transduction Research, and Synthetic Chemistry, Eisai Research Institute, Wilmington, MA, USA.
Daun
J M
JM
Rose
J R
JR
Christ
W J
WJ
Gusovsky
F
F
Chow
J C
JC
D000293:Adolescent; D000328:Adult; D002460:Cell Line; D002746:Chlorpromazine / Q000494:pharmacology*; D005260:Female; D005476:Fluphenazine / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D015850:Interleukin-6 / Q000096:biosynthesis / Q000097:blood; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D008012:Lidocaine / Q000494:pharmacology; D008050:Lipid A / Q000031:analogs & derivatives* / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors* / Q000633:toxicity; D008297:Male; D008875:Middle Aged; D012242:Rhodobacter sphaeroides / Q000276:immunology; D014268:Trifluoperazine / Q000494:pharmacology
C404742:E5564; D015850:Interleukin-6; D008050:Lipid A; D008070:Lipopolysaccharides; D014268:Trifluoperazine; C092845:E 5531; D008012:Lidocaine; D005476:Fluphenazine; D002746:Chlorpromazine